Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma.

ABSTRACT:

Importance

There is substantial interest in capturing cancer treatment tolerability from the patient's perspective using patient-reported outcomes (PROs).

Objective

To examine whether a PRO question, item 5 from the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale (GP5), was associated with early treatment discontinuation (ETD) due to adverse events.

Design, setting, and participants

This prospective survey study was conducted from February to April 2023. Among participants in the ECOG-ACRIN E1A11 trial (a phase 3, parallel design trial conducted between 2013 and 2019), patients with newly diagnosed multiple myeloma were randomized to receive bortezomib (VRd) or carfilzomib (KRd) plus lenalidomide and dexamethasone as induction therapy.

SUBMITTER: Peipert JD 

PROVIDER: S-EPMC10973895 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature